Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alto Neuroscience, Inc.ANRO · Entity 4755 | Director | May 12, 2026 | May 14, 2026 |
| IRONWOOD PHARMACEUTICALS INCIRWD · Entity 5213 | Director | June 10, 2025 | June 12, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alto Neuroscience, Inc.
Report date May 12, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.63 · Expires 2036-05-11 | Direct | 10,958 |
Reported balance
After 2026-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-12 · Grant · Acquired 10,958 · Balance 10,958 F2: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities. F1: The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date.
F2: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities.
IRONWOOD PHARMACEUTICALS INC
Report date June 10, 2025 · Filed June 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 228,313 |
Reported balance
After 2025-06-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-06-10 · Grant · Acquired 45,000 · Balance 228,313 F1: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. F2: Since the date of the reporting person's last ownership report, the individual transferred 4,917 shares of Class A common stock to the individual's ex-spouse pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by the individual's ex-spouse. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year.
F2: Since the date of the reporting person's last ownership report, the individual transferred 4,917 shares of Class A common stock to the individual's ex-spouse pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by the individual's ex-spouse.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2026 Filed May 14, 2026 20:56 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantStock Option (right to buy) · Derivative | 10,958 | $0.00 Strike: $24.63 | $0.00 |
DisclosureSEC source: 0001670893-26-000002 · wk-form4_1778792215.xml · derivative · entry 1 Dreyfus Andrew · CIK 0001670893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,958 Underlying: Common Stock · 10,958 shares Expires 2036-05-11 F2 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities. F1 · derivative.exercise_date: The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:26 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-085437 · ownership.xml · nonDerivative · entry 1 Dreyfus Andrew · CIK 0001670893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,313 F1 · kind: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. F2 · balance_after: Since the date of the reporting person's last ownership report, the individual transferred 4,917 shares of Class A common stock to the individual's ex-spouse pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by the individual's ex-spouse. Read SEC document |
| May 13, 2025 Filed May 15, 2025 20:16 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantStock Option (right to buy) · Derivative | 15,287 | $0.00 Strike: $2.37 | $0.00 |
DisclosureSEC source: 0001999480-25-000039 · wk-form4_1747340182.xml · derivative · entry 1 Dreyfus Andrew · CIK 0001670893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,287 Underlying: Common Stock · 15,287 shares Expires 2035-05-12 F2 · price: The derivative securities were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F1 · derivative.exercise_date: The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 20:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 24,311 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-076211 · ownership.xml · nonDerivative · entry 1 Dreyfus Andrew · CIK 0001670893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,230 F1 · kind: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. F2 · balance_after: Since the date of the reporting person's last ownership report, the individual transferred 5,061 shares of Class A common stock to the individual's ex-spouse pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by the individual's ex-spouse. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:40 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantStock Option (right to buy) · Derivative | 30,574 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002553 · form4-02052024_090236.xml · derivative · entry 1 Dreyfus Andrew · CIK 0001670893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,574 Underlying: Common Stock · 30,574 shares Expires 2034-01-31 F1 · derivative.exercise_date: The shares underlying the option shall vest in 36 equal monthly installments commencing on March 1, 2024, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 21:27 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 22,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-039134 · doc4.xml · nonDerivative · entry 1 Dreyfus Andrew · CIK 0001670893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,980 F1 · kind: The restricted stock, granted pursuant to the Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2023, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. F2 · balance_after: Since the date of the reporting person's last ownership report, the individual transferred 5,009 shares of Class A common stock to the individual's ex-spouse pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by the individual's ex-spouse. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 21,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-033965 · doc4.xml · nonDerivative · entry 1 Dreyfus Andrew · CIK 0001670893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,639 F1 · kind: The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. F2 · balance_after: The total amount of shares beneficially owned has been adjusted to correct prior immaterial computational errors. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 1,431 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-070234 · doc4.xml · nonDerivative · entry 1 Dreyfus Andrew · CIK 0001670893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,077 F1 · kind: Issued pursuant to the Director Compensation Policy, effective as of May 2019. F2 · balance_after: Since the date of the reporting person's last ownership report, the individual transferred 6,014 shares of Class A common stock to the individual's ex-spouse pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by the individual's ex-spouse. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:47 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 1,344 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-056656 · doc4.xml · nonDerivative · entry 1 Dreyfus Andrew · CIK 0001670893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,660 F1 · kind: Issued pursuant to the Director Compensation Policy, effective May 2019. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 20:31 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 1,453 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040921 · doc4.xml · nonDerivative · entry 1 Dreyfus Andrew · CIK 0001670893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,316 F1 · kind: Issued pursuant to the Director Compensation Policy, effective May 2019. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:07 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 22,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038191 · doc4.xml · nonDerivative · entry 1 Dreyfus Andrew · CIK 0001670893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,863 F1 · kind: The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 20:03 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 1,460 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-021299 · doc4.xml · nonDerivative · entry 1 Dreyfus Andrew · CIK 0001670893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,097 F1 · kind: Issued pursuant to the Director Compensation Policy, effective May 2019. F2 · balance_after: Since the date of the reporting person's last ownership report, the individual transferred 5,723 shares of Class A common stock to the individual's ex-spouse pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by the individual's ex-spouse. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:12 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 1,357 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-064043 · doc4.xml · nonDerivative · entry 1 Dreyfus Andrew · CIK 0001670893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,360 F1 · kind: Issued pursuant to the Director Compensation Policy, effective May 2019. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 20:12 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-050875 · doc4.xml · nonDerivative · entry 1 Dreyfus Andrew · CIK 0001670893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,003 F1 · kind: Issued pursuant to the Director Compensation Policy, effective May 2019. Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 21:49 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 1,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037035 · doc4.xml · nonDerivative · entry 1 Dreyfus Andrew · CIK 0001670893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,403 F1 · kind: Issued pursuant to the Director Compensation Policy, effective May 2019. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 20:32 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 21,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034693 · doc4.xml · nonDerivative · entry 1 Dreyfus Andrew · CIK 0001670893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,658 F1 · kind: The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:04 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 1,596 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-019543 · doc4.xml · nonDerivative · entry 1 Dreyfus Andrew · CIK 0001670893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,938 F1 · kind: Issued pursuant to the Director Compensation Policy, effective May 2019. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 21:02 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 1,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-060843 · doc4.xml · nonDerivative · entry 1 Dreyfus Andrew · CIK 0001670893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,342 F1 · kind: Issued pursuant to the Director Compensation Policy, effective May 2019. Read SEC document |
| September 13, 2019 Filed Sep 16, 2019 20:53 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 1,692 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-049666 · doc4.xml · nonDerivative · entry 1 Dreyfus Andrew · CIK 0001670893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,072 F1 · kind: Issued pursuant to the Director Compensation Policy, effective as of May 2019. Read SEC document |
| June 14, 2019 Filed Jun 18, 2019 20:16 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 1,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-037676 · doc4.xml · nonDerivative · entry 1 Dreyfus Andrew · CIK 0001670893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,380 F1 · kind: Issued pursuant to the director compensation policy. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 22,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-033621 · doc4.xml · nonDerivative · entry 1 Dreyfus Andrew · CIK 0001670893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,813 F1 · kind: The restricted stock, granted pursuant to the director compensation policy, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 21:27 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 16,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-035245 · doc4.xml · nonDerivative · entry 1 Dreyfus Andrew · CIK 0001670893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,107 F1 · kind: Issued pursuant to the Director Compensation Plan, effective as of January 2014. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 20:57 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 15,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-037350 · doc4.xml · nonDerivative · entry 1 Dreyfus Andrew · CIK 0001670893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,884 F1 · kind: Issued pursuant to the Director Compensation Plan, effective as of January 2014. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.